Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer
NCT ID: NCT07346807
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
69 participants
INTERVENTIONAL
2026-01-01
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study aims to learn whether surgical disruption of the lingual nerve can enhance the effectiveness of neoadjuvant chemoimmunotherapy before definitive surgery in adults with locally advanced (cT3/T4) tongue cancer. The main questions it aims to answer are:
Can lingual nerve disruption combined with neoadjuvant chemoimmunotherapy improve tumor response prior to surgery?
Is this combined treatment approach safe and feasible for patients with locally advanced tongue cancer?
This is a single-arm, phase II clinical trial.
Participants will:
Undergo tumor biopsy with simultaneous surgical disruption of the affected-side lingual nerve.
Receive neoadjuvant chemoimmunotherapy consisting of tislelizumab, cisplatin, and nab-paclitaxel for two treatment cycles.
Undergo definitive surgical resection of the primary tumor and neck dissection.
Attend scheduled follow-up visits for safety assessments, imaging evaluations, and collection of blood samples for immune monitoring.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Single-Arm Study（NCLDR）
NCT07028918
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
NCT04870905
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
NCT05000892
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
NCT04833257
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
NCT06366945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lingual Nerve Disruption + Neoadjuvant Chemoimmunotherapy
Lingual Nerve Disruption
Surgical transection of 1 cm of the lingual nerve via intraoral approach under local anesthesia at the time of biopsy. This procedure induces ipsilateral tongue tip numbness to enhance subsequent chemoimmunotherapy efficacy.
Tislelizumab
Anti-PD-1 monoclonal antibody administered intravenously at 200 mg on day 1 of each 3-week cycle.
Albumin-bound Paclitaxel
Chemotherapy agent administered intravenously at 260 mg/m² on day 2 of each 3-week cycle.
Cisplatin
Chemotherapy agent administered intravenously at 75 mg/m² on day 2-3 of each 3-week cycle.
Peripheral Blood Collection for Immune Monitoring
Peripheral blood (10 mL) collected in the morning under fasting conditions at baseline, before each cycle of neoadjuvant therapy, and during follow-up visits. Plasma and peripheral blood mononuclear cells are prepared within 2 hours and stored at -80°C for immune cell dynamic analysis.
Pain and Quality of Life Assessment
McGill Pain Questionnaire and quality-of-life surveys administered before each cycle of neoadjuvant therapy to assess treatment impact on pain relief and functional outcomes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lingual Nerve Disruption
Surgical transection of 1 cm of the lingual nerve via intraoral approach under local anesthesia at the time of biopsy. This procedure induces ipsilateral tongue tip numbness to enhance subsequent chemoimmunotherapy efficacy.
Tislelizumab
Anti-PD-1 monoclonal antibody administered intravenously at 200 mg on day 1 of each 3-week cycle.
Albumin-bound Paclitaxel
Chemotherapy agent administered intravenously at 260 mg/m² on day 2 of each 3-week cycle.
Cisplatin
Chemotherapy agent administered intravenously at 75 mg/m² on day 2-3 of each 3-week cycle.
Peripheral Blood Collection for Immune Monitoring
Peripheral blood (10 mL) collected in the morning under fasting conditions at baseline, before each cycle of neoadjuvant therapy, and during follow-up visits. Plasma and peripheral blood mononuclear cells are prepared within 2 hours and stored at -80°C for immune cell dynamic analysis.
Pain and Quality of Life Assessment
McGill Pain Questionnaire and quality-of-life surveys administered before each cycle of neoadjuvant therapy to assess treatment impact on pain relief and functional outcomes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed primary tongue squamous cell carcinoma (cT3 or cT4).
3. Patients scheduled to receive 2 cycles of preoperative neoadjuvant chemoimmunotherapy with tirelizumab, cisplatin, and albumin-bound paclitaxel.
4. Patients planned to undergo surgical resection of tongue cancer following neoadjuvant therapy.
5. Voluntary participation with signed informed consent, good compliance, and willingness to follow study procedures.
Exclusion Criteria
2. History of tongue squamous cell carcinoma or other malignant tumors of the tongue within the past 5 years.
3. Active infection requiring systemic therapy; non-infectious pneumonia or interstitial lung disease requiring steroid therapy, or current pneumonia/interstitial lung disease; known hepatitis B infection (HBsAg positive) or active hepatitis C infection (detectable HCV RNA); known HIV infection.
4. Previous allogeneic tissue or organ transplantation.
5. Unresolved ≥Grade 2 (CTCAE v5.0) toxicities from prior anticancer treatments, except alopecia.
6. Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, NYHA class ≥II heart disease within 3 months prior to enrollment).
7. Active serious clinical infections (\>Grade 2 NCI-CTCAE v5.0).
8. Uncontrolled hypertension (treated systolic BP \>150 mmHg and/or diastolic BP \>90 mmHg) or clinically significant cardiovascular disease, including recent cerebrovascular accident or myocardial infarction (≤6 months), unstable angina, NYHA class ≥II congestive heart failure, or severe arrhythmia not controlled by medication that could affect study treatment.
9. Laboratory abnormalities:
Hematology: WBC \<3,000/mm³, Hb \<8 g/dL, platelets \<80,000/mm³ Liver function: ALT/AST \>3× upper limit of normal, bilirubin \>1.5× ULN Renal function: serum creatinine \>1.5× ULN, renal failure requiring dialysis Diabetes: poorly controlled (FBG \>10 mmol/L) Proteinuria: urine protein ≥++ and 24-hour urine protein \>1.0 g
10. Pregnant women; breastfeeding women must discontinue breastfeeding to participate.
11. History of substance abuse or psychiatric disorders that would interfere with study participation.
12. Participation in another clinical trial within 30 days prior to enrollment.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2025-792R
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.